Last mentioned: Mar 9, 2026
Trial Failure Announced
Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.
Phase II Data Review
Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.
Combination Trials Launch
Roche expanded the program to include combination therapies with CDK4/6 inhibitors.
Roche shares declined following the announcement that its oral SERD, giredestrant, failed to meet the primary endpoint in a pivotal Phase III trial for advanced breast cancer. The setback marks a significant blow to Roche's efforts to regain dominance in the HR-positive, HER2-negative oncology market.
Roche's stock fell on March 9, 2026, following the failure of its oral breast cancer candidate in a key clinical trial. This setback complicates the Swiss pharmaceutical giant's efforts to modernize its oncology portfolio and compete in the lucrative oral SERD market.